Latest news
The 10th edition of DDD will take place on the 11th of Dec 2026 at the School of Pharmacy.
Latest Publications
(truncated titles)
Edoo, Z., et al. Alpibectir–Ethionamide combination (AlpE) for the treatment of tuberculosis. Nat. Commun.,2026. link
Lesire, L., et al Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin-degrading enzyme, a new molecular vulnerability in multiple myeloma. British Journal of Pharmacology,link
El Bakali, J., et al Discovery of pyrimidine-based small activators of Insulin Degrading Enzyme. European Journal of Medicinal Chemistry,link
Valderrama, K., et al. Optimizing the Antibiotic Potency and Metabolic Stability of Pyridomycin Using a Semisynthetic Approach. J. Med. Chem. link
Mourot, L., et al. A new chemotype that opens the S2∗ pocket of the 3CL protease exhibits antiviral activity against SARS-CoV-2. Eur. J. Med. Chem. link
Follow us on 
We celebrate our 20th Anniversary !
Therapeutic Innovation : Discovery Across Boundaries: U1177 (formerly U761), directed by Pr. Benoit Deprez, is dedicated to drug design, discovery and selection. The Lab's mission is to design and study compounds that modulates selected molecular targets in a desired way to treat infectious and metabolic diseases. Our projects engage researchers across physical, chemical and biological sciences to trade ideas and knowledge and sincerely endeavor to validate new therapeutic concepts with drug prototypes and bring drugs candidates to the clinic.
- Developing cutting edge methods for quantitative pharmacology (High Content Screening, Pharmacokinetics)
- Designing the next generation of anti-TB antibiotics : ethionamide boosters.
- Deciphering the role(s) of Insulin Degrading Enzyme in diabetes with several families of modulators.
- Modulating the molecular interplay between intestine, liver and muscles with TGR5 ligands to treat diabetes.
- Developing small chemical modulators of antigenic presentation.
We are open to any type of collaboration with biologists or chemist from academia and industry where medicinal chemistry, in vitro pharmacology and pharmacokinetics enable or accelerate the translation of new therapeutic concept into drug discovery.
Our researchers are committed to the highest standards of scientific quality and integrity in everything they do. We use up-to date electronic lab books to sustainably capitalize knowledge and facilitate collaborations between multiple research sites.
Most of our researchers are also faculty members who teach in PharmD and MSc courses in pharmacy, drug discovery, medicinal chemistry, organic chemistry, and R&D strategies.
A journey with the team
AcrAB-TolC efflux pump inhibitors to potentiate antibiotic efficacy against E.coli et K.pneumoniae
This study refines the SAR of pyridylpiperazine-based efflux pump inhibitors and represents a significant step toward their future in vivo validation as antibiotic adjuvants against AMR in E. coli and K. pneumoniae.
Meurillon, V., Jiménez-Castellanos, J.-C., Vieira Da Cruz, A., et al Enhancing antibiotic activity against Escherichia coli and Klebsiella pneumoniae with optimised pyridylpiperazine AcrAB-TolC efflux pump inhibitors, European Journal of Medicinal Chemistry, 2026, 319, 119200.
Alpibectir–Ethionamide combination (AlpE) for the treatment of tuberculosis.
Alpibectir is a first-generation inhibitor of the mycobacterial transcription regulator VirD, currently in clinical trials for the treatment of multiresistant tuberculosis in combination with ethionamide. We describe here in detail, the mechanism of action of this new drug candidate
Edoo, Z., Grosse, C., Maitre, T. et al. Alpibectir–Ethionamide combination (AlpE) for the treatment of tuberculosis. Nat Commun (2026). volume 17, Article number: 4954
IDE emerges as a novel biomarker and therapeutic vulnerability in Multiple Myeloma
The study demonstates the relevance of IDE inhibitors as boosters of PIs to better treat patients resistant multiple myeloma
Lesire, L., et al Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin-degrading enzyme, a new molecular vulnerability in multiple myeloma -British Journal of Pharmacology,2026
Member of networks Chembioscreen and Chembiofrance
